U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07522697) titled 'Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4' on April 01.
Brief Summary: MITO END-4 is a prospective, single arm, multicentric phase II trial aiming to assess whether Inavolisib is effective in the treatment of advanced endometrial carcinoma with pathogenic PIK3CA mutation. Approximately 48 patients with PIK3CA mutation will be overall enrolled in the study.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Endometrial Cancer
Intervention:
DRUG: Inavolisib
The planned starting dose for inavolisib will be 9 mg PO QD taken on Days 1-28 of each 28-day cycle. Dosing will continue until d...